EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

David Pesqué, Andrea Ciudad, Evelyn Andrades, Dulce Soto, Ramon Gimeno, Ramon M Pujol, Ana M Giménez-Arnau

Acta Dermato-Venereologica · 2024

DOI: 10.2340/actadv.v104.25576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von David Pesqué und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital del Mar Research Institute, Department of Medicine, Autonomous University of Barcelona/Universitat Autonoma de Ba…. Hauptthemen laut MEDLINE: Urticaria, Solar, Urticaria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median increase in Urticaria Control Test was evidenced after omalizumab prescription in all patients. Drug survival at 48 months was at 88.9%. Omalizumab stepping-down protocol led to sustained omalizumab discontinuation in only 1 patient. Median basal Urticaria Control Test was lower (p < 0.01) in patients who were prescribed omalizumab and in patients without remission. This study contributes to our knowledge of omalizumab outcomes in real-life clinical practice and highlights the pathogenic importance of IgE-mediated pathways in solar urticaria, where FcεRI emerges as a possible biomarker of omalizumab response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urticaria, SolarUrticariaHumansFollow-Up StudiesOmalizumabImmunoglobulin E

Substanzen

OmalizumabImmunoglobulin E

Autor:innen und Institutionen

  • Department of Dermatology, Hospital del Mar Research Institute, Department of Medicine, Autonomous University of Barcelona/Universitat Autonoma de Barcelona (UAB), Barcelona, Spain.
  • Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain.
  • Department of Immunology, IMIM Hospital del Mar Research Institute, Barcelona, Spain.
  • DDepartment of Immunology, IMIM Hospital del Mar Research Institute, Barcelona, Spain.
  • DDepartment of Dermatology, Hospital del Mar Research Institute. Universitat Pompeu Fabra, Barcelona, Spain. anamariagimenezarnau@gmail.com.

Zitieren

APA

Pesqué, D., Ciudad, A., Andrades, E., Soto, D., Gimeno, R., Pujol, R. M., & Giménez-Arnau, A. M. (2024). Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.25576

Vancouver

Pesqué D, Ciudad A, Andrades E, Soto D, Gimeno R, Pujol RM, et al. Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes. Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.25576

BibTeX
@article{Pesqu2024,
  author = {Pesqué, David and Ciudad, Andrea and Andrades, Evelyn and Soto, Dulce and Gimeno, Ramon and Pujol, Ramon M and Giménez-Arnau, Ana M},
  title = {Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes},
  journal = {Acta Dermato-Venereologica},
  year = {2024},
  doi = {10.2340/actadv.v104.25576}
}
Kostenlos starten →